HC Wainwright Expects Weaker Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Stock analysts at HC Wainwright dropped their Q2 2026 EPS estimates for shares of Rockwell Medical in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.02) per share for the quarter, down from their previous estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.05) EPS.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.05). The company had revenue of $18.35 million during the quarter, compared to analyst estimates of $18.58 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%.

Several other brokerages also recently commented on RMTI. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Rockwell Medical presently has a consensus rating of “Hold” and an average price target of $2.00.

Rockwell Medical Price Performance

Shares of NASDAQ RMTI opened at $0.93 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.63. Rockwell Medical has a 1-year low of $0.78 and a 1-year high of $2.10. The company has a market capitalization of $36.77 million, a price-to-earnings ratio of -6.22 and a beta of 1.70. The business has a 50-day moving average of $1.00 and a 200-day moving average of $1.03.

Institutional Trading of Rockwell Medical

A number of hedge funds and other institutional investors have recently modified their holdings of RMTI. Panagora Asset Management Inc. acquired a new position in shares of Rockwell Medical in the second quarter worth about $41,000. XTX Topco Ltd increased its holdings in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after purchasing an additional 46,029 shares during the last quarter. Jane Street Group LLC purchased a new stake in Rockwell Medical during the 4th quarter worth approximately $84,000. GSA Capital Partners LLP raised its position in shares of Rockwell Medical by 635.1% in the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares in the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.